Table 3. Relationship between ING5 expression and clinicopathological features of the non-basal triple negative breast cancer.

Clinicopathological Features	n	Nuclear ING5 expression						Cytoplasmic ING5 expression
		–	+	++	+++	PR(%)	p	–	+	++	+++	PR(%)	p
Age (years)
< 45	29	4	7	10	8	86.2	0.299	0	20	8	1	100.0	0.484
≥ 45	139	10	25	62	42	92.8		26	63	43	7	81.3
Tumor size(cm)
< 2.5	87	9	18	36	24	89.7		18	47	21	1	79.3
≥ 2.5	74	5	14	33	22	93.2	0.495	7	33	27	7	90.5	0.001
Pathological classification
Invasive ductal cancer	142	13	27	60	42	90.2	0.634	21	71	43	7	85.2	0.136
Invasive lobular cancer	9	1	2	4	2	88.9		4	3	1	1	55.6
Lymphatic vessel invasion
+	19	2	3	8	6	89.5	0.701	1	12	4	2	94.7	0.569
–	54	0	14	21	19	100.0		9	26	19	0	83.3
Lymph node metastasis
+	77	4	15	35	23	94.8	0.486	11	38	24	4	85.7	0.426
–	79	10	14	32	23	87.3		15	39	21	4	81.0
TNM Staging
I–II	51	10	9	23	9	80.4		9	22	15	5	82.4
III–IV	7	1	0	4	2	85.7	0.296	2	2	3	0	71.4	0.727
ER expression
+	104	8	19	50	27	92.3	0.931	16	52	31	5	84.6	0.905
–	49	6	9	19	15	87.8		7	26	14	2	85.7
PR expression
+	90	6	16	45	23	93.3	0.743	14	46	26	4	84.4	0.800
–	63	8	12	24	19	87.3		9	32	19	3	85.7
Her2 expression
+	93	9	17	42	25	90.3	0.712	15	50	26	2	83.9	0.201
–	58	5	10	26	17	91.4		8	27	18	5	86.2
p53 expression
+	63	1	11	25	26	98.4	0.045	10	33	18	2	84.1	0.896
–	32	2	8	15	7	93.8		3	20	8	1	90.6
Ki-67 percentage (%)
< 50	135	13	23	61	38	90.4	0.771	21	68	41	5	84.4	0.354
≥ 50	19	1	4	8	6	94.7		2	9	6	2	89.5

PR , positive rate; TNM, tumor node metastasis; ER, estrogen receptor; PR, progesterone receptor.